Kristina Hool, MD
Hematology & Oncology · Bozeman, MTNPI 1154556702
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,012 and has fallen 98.3% since, to $17 in 2024.
Across 72 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$169
- Johnson & Johnson$132
- Seagen Inc.$101
- Lilly USA, LLC$83
- Exelixis Inc.$71
- Incyte Corporation$67
- plus $719 from 21 others
What the payments were for
- Food & beverage$1,31498%
- Education$262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $169 |
| Johnson & Johnson | 6 | $132 |
| Seagen Inc. | 6 | $101 |
| Lilly USA, LLC | 5 | $83 |
| Exelixis Inc. | 4 | $71 |
| Incyte Corporation | 3 | $67 |
| Pfizer | 4 | $65 |
| Jazz Pharmaceuticals Inc. | 3 | $60 |
| Sanofi | 3 | $60 |
| Novartis | 3 | $56 |
| Amgen | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Bayer | 2 | $36 |
| Bristol Myers Squibb | 2 | $30 |
| Pharming Healthcare, Inc. | 1 | $27 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| EMD Serono, Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Merck | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
How this compares
$1,341 in reported general payments places this provider in the 55th percentile of 37 hematology & oncology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 17 | $381 |
| Fluconazole | 11 | $304 |
| Anastrozole | 13 | $240 |
| Acyclovir | 29 | $196 |
| Ondansetron Hcl | 26 | $186 |
| Prochlorperazine Maleate | 16 | $167 |
| Oxycodone Hcl | 11 | $116 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Bozeman
- Mark HancockBozeman$6K
- Courtney Regan WagnerBozeman$2K
- William ConkrightBozeman$1K
- Dhimant PatelBozeman$337
- Jack HensoldBozeman$99
- Annie CastilloBozeman$38
- Patrick CobbBillings$21K
- Thomas WeinerHelena$14K
- Aaron FrankeSidney$11K
- Carolyn AksHavre$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.